Cumyl-BC-HpMeGaClone-221 (Cumyl-BC[2.2.1]HpMeGaClone, SGT-271) is a gamma-carboline derivative which is a synthetic cannabinoid that has been sold as a designer drug.[1] It was first identified in Germany in September 2020.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H30N2O |
Molar mass | 410.561 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Malaca S, Tini A, Umani Ronchi F (January 2022). "Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights". Acta Bio-Medica. 92 (6): e2021546. doi:10.23750/abm.v92i6.12696. PMC 8823589. PMID 35075053.
- ^ European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 978-92-9497-558-4.